SEC Info - Laboratory Corp. of America Holdings - ‘10-K’ for 12/31/22

Laboratory Corp. of America Holdings – ‘10-K’ for 12/31/22 – ‘EX-24.10’

On: Tuesday, 2/28/23, at 2:06pm ET · For: 12/31/22 · Accession #: 920148-23-17 · File #: 1-11353

Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 3.73M 2: EX-10.12 Material Contract HTML 1.25M 3: EX-10.18 Material Contract HTML 376K 4: EX-21.1 Subsidiaries List HTML 63K 5: EX-23.1 Consent of Expert or Counsel HTML 28K 6: EX-23.2 Consent of Expert or Counsel HTML 28K 7: EX-24.1 Power of Attorney HTML 30K 16: EX-24.10 Power of Attorney HTML 30K 8: EX-24.2 Power of Attorney HTML 30K 9: EX-24.3 Power of Attorney HTML 30K 10: EX-24.4 Power of Attorney HTML 30K 11: EX-24.5 Power of Attorney HTML 30K 12: EX-24.6 Power of Attorney HTML 30K 13: EX-24.7 Power of Attorney HTML 30K 14: EX-24.8 Power of Attorney HTML 30K 15: EX-24.9 Power of Attorney HTML 30K 17: EX-31.1 Certification -- §302 - SOA'02 HTML 33K 18: EX-31.2 Certification -- §302 - SOA'02 HTML 33K 19: EX-32.1 Certification -- §906 - SOA'02 HTML 31K 25: R1 Document and Entity Information Document HTML 95K 26: R2 Consolidated Statements of Cash Flows HTML 129K 27: R3 Cover HTML 31K 28: R4 Other Liabilities HTML 38K 29: R5 Other Liabilities HTML 37K 30: R6 Other Liabilities HTML 40K 31: R7 Consolidated Balance Sheets HTML 144K 32: R8 Consolidated Statements of Operations HTML 107K 33: R9 Consolidated Statements of Comprehensive Earnings HTML 70K 34: R10 Consolidated Statements of Changes in HTML 90K Shareholders' Equity 35: R11 Summary of Significant Accounting - Earnings Per HTML 67K Share 36: R12 Summary of Significant Accounting - Property, HTML 49K Plant and Equipment 37: R13 Summary of Significant Accounting - Intangible HTML 49K Assets 38: R14 Summary of Significant Accounting Policies HTML 104K 39: R15 Revenue (Notes) HTML 155K 40: R16 Business Acquisitions HTML 91K 41: R17 Restructuring and Related Activities HTML 55K 42: R18 Leases (Notes) HTML 85K 43: R19 Property, Plant and Equipment, Net HTML 43K 44: R20 Goodwill and Intangible Assets HTML 89K 45: R21 Accrued Expenses and Other HTML 37K 46: R22 Debt HTML 68K 47: R23 Preferred Stock and Common Shareholders' Equity HTML 69K 48: R24 Income Taxes HTML 123K 49: R25 Stock Compensation Plans HTML 104K 50: R26 Commitments and Contingent Liabilities HTML 73K 51: R27 Pension and Postretirement Plans HTML 249K 52: R28 Fair Value Measurements HTML 86K 53: R29 Derivative Instruments and Hedging Activities HTML 57K 54: R30 Supplemental Cash Flow Information HTML 40K 55: R31 Business Segment Information HTML 88K 56: R32 Subsequent Events HTML 30K 57: R33 Summary of Significant Accounting Policies HTML 153K (Policies) 58: R34 Summary of Significant Accounting Policies HTML 70K (Tables) 59: R35 Revenue (Tables) HTML 117K 60: R36 BUSINESS ACQUISITIONS & DISPOSITIONS Business HTML 34K Acquisitions (Tables) 61: R37 Restructuring and Related Activities (Tables) HTML 52K 62: R38 Leases (Tables) HTML 112K 63: R39 Property, Plant and Equipment, Net (Tables) HTML 42K 64: R40 Goodwill and Intangible Assets (Tables) HTML 94K 65: R41 Accrued Expenses and Other (Tables) HTML 38K 66: R42 Debt (Tables) HTML 84K 67: R43 Preferred Stock and Common Shareholders' Equity HTML 70K (Tables) 68: R44 Income Taxes (Tables) HTML 128K 69: R45 Stock Compensation Plans (Tables) HTML 82K 70: R46 PENSION AND POSTRETIREMENT PLANS Pension and HTML 243K Postretirement Plans (Tables) 71: R47 Fair Value Measurements (Tables) HTML 66K 72: R48 Derivative Instruments and Hedging Activities HTML 56K (Tables) 73: R49 Supplemental Cash Flow Information (Tables) HTML 40K 74: R50 Business Segment Information (Tables) HTML 84K 75: R51 Summary of Significant Accounting Policies HTML 89K (Details) 76: R52 Revenue (Details) HTML 152K 77: R53 Receivables, Loans, Notes Receivable, and Others HTML 68K (Details) 78: R54 Business Acquisitions (Details) HTML 191K 79: R55 Business Acquisitions & Dispositions Dispositions HTML 92K (Details) 80: R56 BUSINESS ACQUISITIONS & DISPOSITIONS Envigo HTML 90K (Details) 81: R57 Restructuring and Related Activities (Details) HTML 76K 82: R58 Leases (Details) HTML 40K 83: R59 Leases - Lease Cost (Details) HTML 37K 84: R60 LEASES - Supplemental Cash Flow (Details) HTML 39K 85: R61 LEASES - Supplemental Balance Sheet (Details) HTML 58K 86: R62 LEASES - Maturity of Leases (Details) HTML 72K 87: R63 Property, Plant and Equipment, Net (Details) HTML 63K 88: R64 Goodwill and Intangible Assets (Details) HTML 69K 89: R65 Goodwill and Intangible Assets - Schedule of HTML 52K Goodwill (Details) 90: R66 Goodwill and Intangible Assets - Components of HTML 75K Identifiable Intangible Assets (Details) 91: R67 Goodwill and Intangible Assets - Summary of HTML 49K Acquired Amortizable Intangible Assets (Details) 92: R68 Accrued Expenses and Other (Details) HTML 38K 93: R69 Debt - Schedule of Short-Term Debt (Details) HTML 43K 94: R70 Debt - Schedule of Long-Term Debt (Details) HTML 69K 95: R71 Debt - Credit Facilities (Details) HTML 52K 96: R72 Debt - Covertible Subordinated Notes (Details) HTML 39K 97: R73 Debt - Senior Notes (Details) HTML 70K 98: R74 Preferred Stock and Common Shareholders' Equity HTML 166K (Details) 99: R75 Income Taxes (Details) HTML 200K 100: R76 Stock Compensation Plans (Details) HTML 141K 101: R77 Pension and Postretirement Plans (Details) HTML 257K 102: R78 Pension and Postretirement Plans - Fair Value of HTML 171K Plan Assets (Details) 103: R79 Pension and Postretirement Plans, Other HTML 107K Disclosures (Details) 104: R80 PENSION AND POSTRETIREMENT PLANS - Funded Status HTML 45K (Details) 105: R81 Fair Value Measurements (Details) HTML 75K 106: R82 Derivative Instruments and Hedging Activities HTML 66K (Schedule of Derivative Instruments in Statement of Financial Position at Fair Value) (Details) 107: R83 Derivative Instruments and Hedging Activities HTML 58K (Effects of Interest Rate Swap on Other Comprehensive Income) (Details) 108: R84 Supplemental Cash Flow Information (Details) HTML 36K 109: R85 Business Segment Information (Details) HTML 118K 110: R86 Subsequent Events (Details) HTML 37K 111: R9999 Uncategorized Items - lh-20221231.htm HTML 38K 114: XML IDEA XML File -- Filing Summary XML 194K 112: XML XBRL Instance -- lh-20221231_htm XML 4.66M 113: EXCEL IDEA Workbook of Financial Reports XLSX 263K 21: EX-101.CAL XBRL Calculations -- lh-20221231_cal XML 226K 22: EX-101.DEF XBRL Definitions -- lh-20221231_def XML 1.48M 23: EX-101.LAB XBRL Labels -- lh-20221231_lab XML 2.84M 24: EX-101.PRE XBRL Presentations -- lh-20221231_pre XML 2.06M 20: EX-101.SCH XBRL Schema -- lh-20221231 XSD 242K 115: JSON XBRL Instance as JSON Data -- MetaLinks 716± 1.12M 116: ZIP XBRL Zipped Folder -- 0000920148-23-000017-xbrl Zip 1.42M

KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra van der Vaart his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, in connection with the Laboratory Corporation of America Holdings (Corporation) Annual Report on Form 10-K for the year ended December 31, 2022, under the Securities Exchange Act of 1934, as amended, including, without limiting the generality of the foregoing, to sign the Form 10-K in the name and on behalf of the Corporation or on behalf of the undersigned as a director or officer of the Corporation, and any amendments to the Form 10-K and any instrument, contract, document or other writing, of or in connection with the Form 10-K or amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, including this power of attorney, with the Securities and Exchange Commission and any applicable securities exchange or securities self-regulatory body, granting unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents, each acting alone, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

This ‘10-K’ Filing

Date

Other Filings

Filed on:

2/28/23

None on these Dates

For Period end:

12/31/22

List all Filings

As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/26/24 Lab Corp. of America Holdings 10-K 12/31/23 122:18M 5/04/23 Lab Corp. of America Holdings 10-Q 3/31/23 56:6.4M

As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/26/21 Lab Corp. of America Holdings 8-K:1,9 5/26/21 12:520K Donnelley … Solutions/FA 5/04/21 Lab Corp. of America Holdings 10-Q 3/31/21 72:8.9M 3/03/21 Lab Corp. of America Holdings 8-K/A:4,9 11/02/20 13:182K 2/25/21 Lab Corp. of America Holdings 10-K 12/31/20 116:19M 11/05/20 Lab Corp. of America Holdings 8-K:4,9 11/02/20 11:147K Donnelley … Solutions/FA 7/31/20 Lab Corp. of America Holdings 10-Q 6/30/20 80:12M 5/08/20 Lab Corp. of America Holdings 10-Q 3/31/20 78:73M 11/25/19 Lab Corp. of America Holdings 8-K:1,9 11/25/19 12:504K Donnelley … Solutions/FA 6/05/19 Lab Corp. of America Holdings 8-K:5,7,9 6/04/19 3:314K Donnelley … Solutions/FA 6/03/19 Lab Corp. of America Holdings 8-K:1,2,7,9 6/03/19 4:647K Donnelley … Solutions/FA 8/22/17 Lab Corp. of America Holdings 8-K:1,8,9 8/22/17 5:516K Donnelley … Solutions/FA 5/16/16 Lab Corp. of America Holdings 8-K:5,9 5/11/16 3:313K Donnelley … Solutions/FA 1/30/15 Lab Corp. of America Holdings 8-K:1,8,9 1/30/15 7:815K Donnelley … Solutions/FA 11/01/13 Lab Corp. of America Holdings 8-K:1,8,9 10/29/13 5:480K Donnelley … Solutions/FA 11/19/10 Lab Corp. of America Holdings 8-K:1,8,9 11/16/10 6:1.2M 2/26/08 Lab Corp. of America Holdings 10-K 2/26/08 17:1.3M 2/27/07 Lab Corp. of America Holdings 10-K 12/31/06 17:1.2M Edgar Ease Svc Bureau/FA 8/08/05 Lab Corp. of America Holdings 10-Q 8/08/05 8:511K 3/03/05 Lab Corp. of America Holdings 10-K 3/03/05 17:1.4M 11/01/04 Lab Corp. of America Holdings 10-Q 11/01/04 6:486K 3/18/02 Lab Corp. of America Holdings 10-K 12/31/01 7:582K 10/19/01 Lab Corp. of America Holdings S-3 8:538K Davis Polk & … LLP 01/FA

Laboratory Corp. of America Holdings – ‘10-K’ for 12/31/22 – ‘EX-24.10’

On: Tuesday, 2/28/23, at 2:06pm ET · For: 12/31/22 · Accession #: 920148-23-17 · File #: 1-11353

Previous ‘10-K’: ‘10-K’ on 2/25/22 for 12/31/21 · Next & Latest: ‘10-K’ on 2/26/24 for 12/31/23 · 24 References:

Annual Report — Form 10-K

Filing Table of Contents

‘EX-24.10’ — Power of Attorney

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein

2 Subsequent Filings that Reference this Filing

22 Previous Filings that this Filing References


			By:			/s/ *R. SANDERS WILLIAMS, M.D.*
						R. Sanders Williams, M.D.

Laboratory Corp. of America Holdings – ‘10-K’ for 12/31/22 – ‘EX-24.10’

On: Tuesday, 2/28/23, at 2:06pm ET · For: 12/31/22 · Accession #: 920148-23-17 · File #: 1-11353

Annual Report — Form 10-KFiling Table of Contents

‘EX-24.10’ — Power of Attorney

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein

2 Subsequent Filings that Reference this Filing

22 Previous Filings that this Filing References

Annual Report — Form 10-K

Filing Table of Contents